Company intelligence / Profile preview
Sun Pharma
Mumbai, Maharashtra, Indiasunpharma.com ↗
- Ownership
- Public · SUNPHARMA
- Employees
- ~41000
- Development stage
- Other
01
Overview
Sun Pharma has a robust global commercial presence with over $5.4 billion in annual revenue. Its specialty pipeline includes ILUMYA™ for moderate-to-severe plaque psoriasis and WINLEVI® for acne vulgaris. The company also markets Cequa for dry eye disease and Odomzo for basal cell carcinoma in the US. It maintains one of the world’s largest portfolios of generic drugs.
- Therapeutic areas
- PsychiatryDermatologyOphthalmologyOncologyCardiovascular
- Modalities
- Small moleculeBiologicMonoclonal antibodyPeptides
- Industry
- Biotech
02
Drug pipeline
62 assets61 more assets in the full pipeline.
03
Partnerships
Merck & Co.: Licensing agreement for tildrakizumabChina Medical System Holdings
Beyond the preview
Go deeper on Sun Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Pharma.